Treatment of Primary Sjögren Syndrome With Rituximab
Authors: Alain Saraux, Emmanuel Nowak, Valérie Devauchelle-Pensec
Journal: Annals of Internal Medicine (2014)

Letters2 September 2014Treatment of Primary Sjögren Syndrome With RituximabAlain Saraux, MD, PhD, Emmanuel Nowak, PhD, and Valérie Devauchelle-Pensec, MD, PhDAlain Saraux, MD, PhDFrom Hôpital de la Cavale Blanche, Brest, France; Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 0502, Centre Hospitalier Universitaire de la Cavale Blanche, Brest, France; and Hôpital de la Cavale Blanche, Brest, France.Search for more papers by this author, Emmanuel Nowak, PhDFrom Hôpital de la Cavale Blanche, Brest, France; Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 0502, Centre Hospitalier Universitaire de la Cavale Blanche, Brest, France; and Hôpital de la Cavale Blanche, Brest, France.Search for more papers by this author, and Valérie Devauchelle-Pensec, MD, PhDFrom Hôpital de la Cavale Blanche, Brest, France; Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 0502, Centre Hospitalier Universitaire de la Cavale Blanche, Brest, France; and Hôpital de la Cavale Blanche, Brest, France.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5017-4 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We fully agree that the ideal primary end point for assessing treatment efficacy in pSS remains unknown and that the best option among those available to date (the VAS, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index [1], the ESSDAI [2], and physician opinion) is undecided. We also concur that the best cutoff for defining an improvement in the VAS score in millimeters or a percentage cannot be reliably determined because we have no data on the minimal clinically important differences for these measures. Therefore, there is no sound basis on which to select patients for biologic ...References1. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al; EULAR Sjögren's Task Force. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011;70:968-72. [PMID: 21345815] doi:10.1136/ard.2010.143743 CrossrefMedlineGoogle Scholar2. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al; EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69:1103-9. [PMID: 19561361] doi:10.1136/ard.2009.110619 CrossrefMedlineGoogle Scholar3. Brown S, Navarro Coy N, Pitzalis C, Emery P, Pavitt S, Gray J, et al; TRACTISS trial team. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome. BMC Musculoskelet Disord. 2014;15:21. [PMID: 24438039] doi:10.1186/1471-2474-15-21 CrossrefMedlineGoogle Scholar4. Tobón GJ, Saraux A, Gottenberg JE, Quartuccio L, Fabris M, Seror R, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum. 2013;65:3218-27. [PMID: 23982978] doi:10.1002/art.38129 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hôpital de la Cavale Blanche, Brest, France; Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 0502, Centre Hospitalier Universitaire de la Cavale Blanche, Brest, France; and Hôpital de la Cavale Blanche, Brest, France.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-1085. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment of Primary Sjögren Syndrome With Rituximab Valérie Devauchelle-Pensec , Xavier Mariette , Sandrine Jousse-Joulin , Jean-Marie Berthelot , Aleth Perdriger , Xavier Puéchal , Véronique Le Guern , Jean Sibilia , Jacques-Eric Gottenberg , Laurent Chiche , Eric Hachulla , Pierre Yves Hatron , Vincent Goeb , Gilles Hayem , Jacques Morel , Charles Zarnitsky , Jean Jacques Dubost , Jacques Olivier Pers , Emmanuel Nowak , and Alain Saraux Metrics Cited ByFuture treatments for Sjögren's syndromeWhich and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome 2 September 2014Volume 161, Issue 5Page: 377-378KeywordsClinical trial reportingCohort studiesDisclosureFatigueForecastingPatients ePublished: 2 September 2014 Issue Published: 2 September 2014 CopyrightCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...